Pharma Mar SA (PHMMF)
94.60
0.00 (0.00%)
USD |
OTCM |
Sep 25, 16:00
Pharma Mar Net Income (TTM) : 65.32M for June 30, 2026
Net Income (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 65.32M |
| March 31, 2026 | 92.94M |
| December 31, 2025 | 86.99M |
| September 30, 2025 | 37.47M |
| June 30, 2025 | 46.55M |
| March 31, 2025 | 21.39M |
| December 31, 2024 | 28.05M |
| September 30, 2024 | 0.7834M |
| June 30, 2024 | -1.851M |
| March 31, 2024 | 2.285M |
| December 31, 2023 | 1.303M |
| September 30, 2023 | 10.05M |
| June 30, 2023 | 22.18M |
| March 31, 2023 | 41.36M |
| December 31, 2022 | 80.66M |
| June 30, 2022 | 92.80M |
| March 31, 2022 | 101.95M |
| December 31, 2021 | 106.43M |
| September 30, 2021 | 72.97M |
| June 30, 2021 | 79.64M |
| March 31, 2021 | 104.30M |
| December 31, 2020 | 152.92M |
| September 30, 2020 | 162.82M |
| June 30, 2020 | 136.31M |
| March 31, 2020 | 78.96M |
| Date | Value |
|---|---|
| December 31, 2019 | -10.63M |
| September 30, 2019 | -31.43M |
| June 30, 2019 | -42.04M |
| March 31, 2019 | -28.67M |
| December 31, 2018 | -19.90M |
| September 30, 2018 | -30.60M |
| June 30, 2018 | -21.95M |
| March 31, 2018 | -31.07M |
| December 31, 2017 | -30.61M |
| September 30, 2017 | -24.46M |
| June 30, 2017 | -20.02M |
| March 31, 2017 | -21.35M |
| December 31, 2016 | -26.60M |
| September 30, 2016 | -19.71M |
| June 30, 2016 | -11.03M |
| March 31, 2016 | -7.721M |
| December 31, 2015 | 7.516M |
| September 30, 2015 | 3.179M |
| June 30, 2015 | -0.731M |
| March 31, 2015 | 2.648M |
| December 31, 2014 | 18.55M |
| September 30, 2014 | 20.53M |
| June 30, 2014 | 19.17M |
| March 31, 2014 | 17.74M |
| December 31, 2013 | 15.54M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (TTM) Benchmarks
| Oryzon Genomics SA | -2.774M |
| Grifols SA | 629.73M |
| ACADIA Pharmaceuticals, Inc. | 380.48M |
| Alkermes Plc | 66.12M |
| Alnylam Pharmaceuticals, Inc. | 807.99M |